Ascentage Pharma Group International 6-K Filing
Ticker: AAPG · Form: 6-K · Filed: Dec 9, 2025 · CIK: 2023311
Sentiment: neutral
Filing Stats: 280 words · 1 min read · ~1 pages · Grade level 14.4 · Accepted 2025-12-09 08:30:23
Filing Documents
- ea0268888-6k_ascentage.htm (6-K) — 14KB
- ea026888801ex99-1_ascentage.htm (EX-99.1) — 26KB
- ea026888801ex99-2_ascentage.htm (EX-99.2) — 28KB
- ea026888801ex99-3_ascentage.htm (EX-99.3) — 25KB
- ex99-1_001.jpg (GRAPHIC) — 10KB
- ex99-2_001.jpg (GRAPHIC) — 10KB
- ex99-3_001.jpg (GRAPHIC) — 10KB
- 0001213900-25-119453.txt ( ) — 137KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2025 Commission File Number: 001-42484 ASCENTAGE PHARMA GROUP INTERNATIONAL (Translation of Registrant’s name into English) 68 Xinqing Road Suzhou Industrial Park Suzhou, Jiangsu China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE On December 8, 2025, Ascentage Pharma Group International issued three press releases entitled (1) “ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment”, (2) “ ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%” and (3) “ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP”. A copy of each press release is furnished as Exhibits 99.1, 99.2 and 99.3 to this Report. 1 INDEX TO EXHIBITS Exhibit Number Exhibit Title 99.1 Press Release dated December 8, 2025 99.2 Press Release dated December 8, 2025 99.3 Press Release dated December 8, 2025 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ASCENTAGE PHARMA GROUP INTERNATIONAL Date: December 9, 2025 /s/ Dajun Yang Name: Dajun Yang Title: Chief Executive Officer 3